The company intends to use the funds to advance its portfolio of age-reprogramming therapies, expand its computational biology teams, and transition its lead liver-cell program into its first human clinical studies.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

901 Gateway Blvd
San Francisco, CA 94080
USA

Phone

Undisclosed

Website

www.newlimit.com

Email Address

Undisclosed

Overview

NewLimit is a biotechnology company working to radically extend human healthspan. We're developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Co-Founder

Brian Armstrong

Co-Founder

Greg Johnson

Co-Founder

Jacob Kimmel

President

Michael Polansky

Browse more venture capital transactions:

Prev: 6/3/2026: Dockwa venture capital transaction
Next: 6/3/2026: Factorial venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary